Administer triamcinolone with caution

Article

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration.

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration, according to the results of a study published online ahead of print by Clinical Ophthalmology.

M. Selim kocabora and co-workers from the Vakif Gureba Education and Research Hospital, Istanbul, Turkey reviewed the records of 122 patients (147 eyes) who had undergone IVTA treatment between 2003 and 2006.

The mean IOP following IVTA injection was statistically significantly higher than pre-injection IOP. Important IOP elevations were observed mostly in the first and second months. In 40 eyes (27.7%), topical anti-glaucomatous therapy was required and seven later required surgical intervention to lower IOP.

The researchers think that IVTA should be administered only after careful planning.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.